P
Philippe Lang
Researcher at University of Paris
Publications - 159
Citations - 8612
Philippe Lang is an academic researcher from University of Paris. The author has contributed to research in topics: Transplantation & Kidney transplantation. The author has an hindex of 47, co-authored 155 publications receiving 7881 citations. Previous affiliations of Philippe Lang include French Institute of Health and Medical Research & Budapest University of Technology and Economics.
Papers
More filters
Journal ArticleDOI
Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group.
Carl G. Groth,Lars Bäckman,José-Maria Morales,Roy Y. Calne,Henri Kreis,Philippe Lang,Jean-Louis Touraine,Kerstin Claesson,Josep M. Campistol,Dominique Durand,L. Wramner,Christina Brattström,Bernard Charpentier +12 more
TL;DR: Sirolimus (rapamycin) is a potent immunosuppressant with a mechanism of action different from cyclosporine (CsA) or tacrolimus as discussed by the authors.
Journal ArticleDOI
Costimulation blockade with belatacept in renal transplantation.
Flavio Vincenti,Christian P. Larsen,Antoine Durrbach,Thomas Wekerle,Björn Nashan,Gilles Blancho,Philippe Lang,Josep M. Grinyó,Philip F. Halloran,Kim Solez,David Hagerty,Elliott Levy,Wenjiong Zhou,Kannan Natarajan,Bernard Charpentier +14 more
TL;DR: Belatacept, an investigational selective costimulation blocker, did not appear to be inferior to cyclosporine as a means of preventing acute rejection after renal transplantation and may preserve the glomerular filtration rate and reduce the rate of chronic allograft nephropathy.
Journal ArticleDOI
Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study
Sylvain Choquet,Véronique Leblond,Raoul Herbrecht,Gérard Socié,Anne-Marie Stoppa,Peter Vandenberghe,Alain Fischer,Franck Morschhauser,Gilles Salles,Walter Feremans,Etienne Vilmer,Marie-Noëlle Peraldi,Philippe Lang,Yvon Lebranchu,Eric Oksenhendler,Jeanne Luce Garnier,Thierry Lamy,Arnaud Jaccard,Augustin Ferrant,Fritz Offner,Olivier Hermine,Anne Moreau,Samira Fafi-Kremer,Patrice Morand,Lucienne Chatenoud,Nathalie Berriot-Varoqueaux,Loïc Bergougnoux,Noel Milpied +27 more
TL;DR: It is concluded that rituximab is effective and safe in PTLD, with stable responses at 1 year, and the response rate and overall survival might be improved by combining ritUXimab with other treatments.
Journal ArticleDOI
Induction Chemotherapy Followed by Either Chemoradiotherapy or Bioradiotherapy for Larynx Preservation: The TREMPLIN Randomized Phase II Study
Jean-Louis Lefebvre,Yoann Pointreau,Frederic Rolland,Marc Alfonsi,Alain Baudoux,Christian Sire,Dominique De Raucourt,Olivier Malard,M. Degardin,C. Tuchais,Emmanuel Blot,Michel Rives,Emile Reyt,Jean Marc Tourani,Lionel Geoffrois,Frederic Peyrade,Francois Guichard,Dominique Chevalier,Emmanuel Babin,Philippe Lang,François Janot,Gilles Calais,Pascal Garaud,Etienne Bardet +23 more
TL;DR: There is no evidence that one treatment was superior to the other or could improve the outcome reported with ICT followed by RT alone, and the protocol that can best compare with RT alone after ICT is still to be determined.
Journal ArticleDOI
Repair of the lower and middle parts of the face by composite tissue allotransplantation in a patient with massive plexiform neurofibroma: a 1-year follow-up study.
Laurent Lantieri,Jean-Paul Meningaud,Philippe Grimbert,Frank Bellivier,Jean-Pascal Lefaucheur,Nicolas Ortonne,Marc-David Benjoar,Philippe Lang,Pierre Wolkenstein +8 more
TL;DR: This case demonstrates the feasibility of surgically removing a large part of the face and replacing it with a composite tissue allograft, which seems to have a satisfactory risk to benefit ratio, and could be offered in rare and selected cases.